NewAmsterdam Pharma Company N.V.

NasdaqGM NAMS

NewAmsterdam Pharma Company N.V. Gross Profit Margin for the year ending December 31, 2023: 100.00%

NewAmsterdam Pharma Company N.V. Gross Profit Margin is 100.00% for the year ending December 31, 2023, a 0.00% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

NewAmsterdam Pharma Company N.V. Gross Profit Margin for the year ending December 31, 2022 was 100.00%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	62
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Key trends

Past 5 years